Here, we report our clinical data to show that EGFR kinase domain mutation-positive NSCLC is associated with dramatic regression of patient's tumor to IPHC followed by cycles of systemic chemotherapy (IPHC-CT) and longer overall survival. This evidence concerns the gene EGFR and non-small cell lung carcinoma.